Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Farnier

Showing results (141-150 of 144) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 144 results.
Expert Opinion on Drug Safety|April 25, 2015
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert PanelMaciej Banach, Manfredi Rizzo, Peter P Toth, et al.
Circulation. Cardiovascular Genetics|September 17, 2015
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal AntibodyPaul N Hopkins, Joep Defesche, Sigrid W Fouchier, et al.
Cardiovascular Diabetology|January 28, 2014
Residual macrovascular risk in 2013: what have we learned?Jean-Charles Fruchart, Jean Davignon, Michel P Hermans, et al.
Cardiovascular Diabetology|June 6, 2019
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) FoundationJean-Charles Fruchart, Raul D Santos, Carlos Aguilar-Salinas, et al.
Pageof 15

Showing results (141-150 of 144) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 144 results.
Expert Opinion on Drug Safety|April 25, 2015
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert PanelMaciej Banach, Manfredi Rizzo, Peter P Toth, et al.
Circulation. Cardiovascular Genetics|September 17, 2015
Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal AntibodyPaul N Hopkins, Joep Defesche, Sigrid W Fouchier, et al.
Cardiovascular Diabetology|January 28, 2014
Residual macrovascular risk in 2013: what have we learned?Jean-Charles Fruchart, Jean Davignon, Michel P Hermans, et al.
Cardiovascular Diabetology|June 6, 2019
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) FoundationJean-Charles Fruchart, Raul D Santos, Carlos Aguilar-Salinas, et al.
Pageof 15